Conceptual illustration of Kissei’s portfolio strategy, showing clinical evidence review, research platforms, a Kissei sign and Japan’s flag.
Kissei’s Tavneos setback is putting pressure on its growth plans. What could this mean for international suppliers and licensing partners? We examine the company’s pipeline, the importance of reliable evidence and how to approach Kissei with a credible Japan proposition.
Stefan speaking on stage at a pharmaceutical industry conference, in front of a large presentation screen about Daiichi Sankyo, antibody-drug conjugates, and new business opportunities in oncology.
Daiichi Sankyo has built one of the pharmaceutical industry’s most productive antibody-drug conjugate platforms. Enhertu has […]
A photorealistic illuminated billboard beside a wet city road at dusk, displaying: "Otsuka's new target is to hit ¥3.5 trillion by 2035."
Large pharmaceutical targets often look like abstract financial noise to external vendors. But Otsuka’s target to […]